Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024)

Vir Biotechnology (VIR) has 5 years of Receivables - Accured data on file, last reported at $5.7 million in Q1 2024.

• For the quarter ending Q1 2024, Receivables - Accured rose 171.43% year-over-year to $5.7 million; the trailing twelve-month figure through Mar 2024 stood at $5.7 million (up 171.43% YoY), and the FY2023 full-year result was $4.0 million, up 60.0% from the prior year.
• Receivables - Accured advanced to $5.7 million in Q1 2024, from $4.0 million in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $5.7 million in Q1 2024 to a low of $600000.0 in Q2 2021.
• A 5-year average of $2.1 million and a median of $1.8 million in 2022 frame the typical range for Receivables - Accured.
• Peak annual rise in Receivables - Accured reached 250.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Tracing VIR's Receivables - Accured over 5 years: stood at $800000.0 in 2020, then jumped by 37.5% to $1.1 million in 2021, then surged by 127.27% to $2.5 million in 2022, then soared by 60.0% to $4.0 million in 2023, then soared by 42.5% to $5.7 million in 2024.
• Business Quant data shows VIR's Receivables - Accured at $5.7 million in Q1 2024, $4.0 million in Q4 2023, and $2.9 million in Q3 2023.